UNI-BIO GROUP (00690) Reports Interim Results with Net Profit of HK$75.955 Million, Up 12.7% Year-over-Year
Stock News
Aug 28
UNI-BIO GROUP (00690) announced its interim results for 2025, reporting revenue of HK$310 million, representing a 13.4% year-over-year increase. Net profit reached HK$75.955 million, up 12.7% compared to the same period last year, with basic earnings per share of 1.27 HK cents.
The period's profit growth was primarily driven by the group's sales channel expansion, increasing demand for Bogutai®, and sustained market attention toward the group's listed pharmaceutical products. This performance also reflects the strategic effectiveness of the group's focus on operational efficiency, stringent cost control, and precise commercial execution, further solidifying its trajectory of sustained profit growth and long-term value creation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.